List of Excipients in Branded Drug GAMUNEX-C

Gamunex-C Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Gamunex-C is a 10% human immune globulin intravenous product manufactured by Grifols. Its formulation uses glycine as the principal stabilizing excipient, with an acidic liquid formulation and no preservative. The commercial value of this strategy is less about exclusivity than about product performance, renal-risk positioning, manufacturing consistency, and compatibility with immunoglobulin supply constraints.

The main opportunities are:

• supplying pharmaceutical-grade glycine and related formulation materials;
• developing alternative stabilizer systems for follow-on immune globulin products;
• improving container, tubing, and device compatibility;
• creating lower-volume or subcutaneous presentations;
• supporting biosimilar or follow-on development under the FDA biologics framework;
• developing manufacturing technologies that preserve IgG activity while reducing aggregation and fragmentation.

Gamunex-C does not have the conventional small-molecule Orange Book patent profile. It is licensed under biologics regulation through BLA 125122 and is assessed through the Purple Book and the 351(a)/351(k) framework rather than ordinary ANDA substitution rules.[1,2]

What excipients are used in Gamunex-C?

Gamunex-C contains human immunoglobulin G at a 10% concentration and glycine as its principal excipient. The product is a ready-to-use liquid with an acidic pH, no antimicrobial preservative, and low sodium content.[1]

Formulation attribute	Gamunex-C profile
Active ingredient	Human normal immunoglobulin G
Protein concentration	10%
Primary stabilizer	Glycine
Dosage form	Sterile liquid for intravenous or subcutaneous administration, depending on presentation and indication
Preservative	None listed in the U.S. prescribing information
pH	Approximately 4.0 to 4.5
Administration	Intravenous infusion; approved subcutaneous use applies to specified presentations and indications
Manufacturer	Grifols Therapeutics LLC
U.S. biologics license	BLA 125122
Principal indications	Primary humoral immunodeficiency, immune thrombocytopenic purpura, and chronic inflammatory demyelinating polyneuropathy

The excipient system is intentionally limited. A low-complexity formulation reduces the number of raw materials requiring qualification and simplifies control of osmolality, particulate matter, extractables, leachables, and container closure interactions.

Why does Gamunex-C use glycine as a stabilizer?

Glycine stabilizes immunoglobulin during processing and storage while providing a relatively simple, well-characterized excipient system. For plasma-derived proteins, the formulation must control aggregation, fragmentation, oxidation, deamidation, and loss of biological activity.

Glycine has several commercial advantages:

1. It is a small, widely available amino acid with established pharmaceutical use.
2. It does not introduce the sucrose-associated renal warning that applies to some intravenous immune globulin products.
3. It supports a preservative-free liquid product.
4. It can be sourced from multiple qualified pharmaceutical-grade suppliers.
5. Its regulatory history is easier to manage than a novel excipient.

The absence of sucrose does not eliminate all renal risk associated with immune globulin therapy. The FDA label still contains renal-risk and thrombosis warnings applicable to immune globulin products generally.[1] The formulation can support a differentiated risk discussion, but it does not justify a claim that Gamunex-C is renal-risk-free.

How does glycine compare with other immune globulin excipients?

Excipient approach	Commercial examples or use	Strategic implication
Glycine	Gamunex-C	Mature supply chain, simple formulation, no sucrose
Sucrose	Used in certain historical immune globulin products	Renal-risk concerns can limit use in susceptible patients
Maltose	Used in some immune globulin formulations	May create blood-glucose monitoring concerns with certain glucose meters
Sorbitol	Used in some protein formulations	Osmolality and tolerability require control
Proline	Used in selected immunoglobulin products	Alternative stabilization platform with different formulation behavior
No or minimal excipient system	Certain specialized biologic designs	Higher dependence on process control and container performance

The formulation opportunity is therefore not limited to replacing glycine. It includes optimizing the interaction between stabilizer concentration, pH, protein concentration, fill volume, infusion rate, and container system.

What formulation patents protect Gamunex-C?

Gamunex-C’s commercial position is not principally based on a current Orange Book patent estate. The product is a biologic, and FDA-approved biologic products are not generally listed in the Orange Book in the same manner as small-molecule products approved under section 505 of the Federal Food, Drug, and Cosmetic Act.[2]

Publicly available regulatory materials identify the product, its BLA, indications, dosage forms, and formulation characteristics. They do not establish a current, enforceable product-specific formulation patent barrier comparable to the patent listings commonly used for branded tablets or injectables.

Earlier patents and patent families may have covered:

• stabilized immunoglobulin compositions;
• low-aggregation immune globulin preparations;
• purification and viral inactivation methods;
• liquid formulations;
• methods for treating immune deficiency and inflammatory disease;
• manufacturing and filling processes.

Most commercially relevant early patent rights for the underlying product technology would have been filed many years ago. Their ordinary 20-year terms make it unlikely that basic formulation patents alone now block follow-on development. Patent expiration does not eliminate trade-secret or process barriers. The key residual barriers are likely to be manufacturing know-how, donor-plasma access, analytical comparability, clinical evidence, and regulatory execution.

Is Gamunex-C protected by Orange Book listings?

No conventional Orange Book listing should be expected for Gamunex-C. The relevant regulatory record is the FDA biologics license and the Purple Book framework.

That distinction affects market entry:

• an ANDA applicant generally cannot rely on simple small-molecule substitution;
• a follow-on biologic applicant must address reference-product comparability and the requirements of section 351(k);
• state pharmacy substitution rules for biosimilars may apply only after an FDA product receives an interchangeable designation;
• product-specific labeling and administration differences can limit automatic substitution even where active ingredient and concentration are similar.

When does Gamunex-C lose exclusivity?

Gamunex-C’s original commercial exclusivity period has already elapsed. It is an established plasma-derived biologic with a long commercial history, and no current regulatory exclusivity should be assumed solely from its reference-product status.

For biologics, exclusivity analysis requires separating four concepts:

Exclusivity type	Relevance to Gamunex-C
FDA reference-product exclusivity	Historical relevance; the product is long established
Orphan-drug exclusivity	Must be assessed by indication and designation, not assumed for the entire product
Patent exclusivity	Depends on individual claims and expiration dates
Manufacturing know-how	May remain commercially important even after patents expire

A competitor does not need to duplicate every aspect of Gamunex-C’s commercial process to enter the immune globulin market. It must establish a product with acceptable identity, purity, potency, safety, consistency, and clinical performance. FDA approval of another immune globulin product does not require identical excipients, but material formulation differences can increase comparability and clinical-development burdens.

What is the FDA regulatory status of Gamunex-C?

Gamunex-C is an FDA-licensed human immune globulin product under BLA 125122. The product is approved for multiple indications and has both intravenous and specified subcutaneous use depending on the presentation and labeling.[1]

The regulatory value of the excipient strategy is tied to the approved label. A formulation change could affect:

• product stability;
• infusion tolerability;
• subcutaneous administration;
• aggregation and immunogenicity;
• container closure integrity;
• extractables and leachables;
• viral safety and purification validation;
• comparability to the currently licensed product.

A change from glycine to another stabilizer would generally require a formal CMC comparability package. The regulatory burden would depend on the scale of the change, the analytical evidence, and whether clinical or bridging data were required.

What commercial opportunities exist around Gamunex-C excipients?

Pharmaceutical-grade glycine supply

Glycine is a commodity-like excipient, but pharmaceutical use requires consistent control of identity, purity, endotoxin, bioburden, heavy metals, residual solvents, particle characteristics, and supply continuity. Suppliers can compete on:

• dual-site manufacturing;
• validated low-endotoxin grades;
• audit readiness;
• long-term supply agreements;
• regional inventory;
• container formats suited to biologics manufacturing;
• change-control discipline.

The opportunity is stable rather than high-margin unless a supplier provides a qualified, difficult-to-replace grade or integrates directly into the manufacturer’s formulation and process validation.

Alternative stabilizer platforms

A follow-on immune globulin developer could evaluate glycine, proline, sorbitol, maltose, or mixed stabilizer systems. The commercial objective would be to improve one or more of the following:

• long-term stability;
• refrigerated shelf life;
• resistance to agitation;
• reduced aggregation;
• lower subcutaneous injection volume;
• improved infusion tolerability;
• compatibility with single-use systems.

A novel excipient is unlikely to be attractive for a conventional follow-on product because it creates additional toxicology and regulatory work. Established excipients with prior parenteral use have a stronger development profile.

Subcutaneous delivery

Subcutaneous immune globulin products create a larger role for excipient and device engineering than standard intravenous products. The formulation must address injection-site tolerability, viscosity, osmolality, concentration, dose volume, and delivery time.

Commercial opportunities include:

• higher-concentration liquid formulations;
• wearable infusion systems;
• prefilled syringes;
• dual-cartridge devices;
• low-volume administration;
• excipient systems that maintain stability at higher protein concentration.

The competitive objective is not simply to reproduce Gamunex-C. It is to improve convenience while preserving IgG integrity and minimizing local reactions.

Container and administration-system compatibility

Immune globulin products are sensitive to agitation, temperature excursions, surface adsorption, and contact with tubing or elastomers. Suppliers can create value through:

• low-sorption bags and vials;
• optimized stopper and seal materials;
• compatible infusion tubing;
• reduced particulate generation;
• validated cold-chain packaging;
• real-time excursion monitoring.

These technologies may be protected by device or packaging patents even when the underlying drug formulation is not strongly protected.

Which companies are competing with Gamunex-C?

Gamunex-C competes in the crowded immune globulin market rather than in a single-product market. Relevant competitors include products marketed by CSL Behring, Takeda, Grifols, Octapharma, Kedrion, ADMA Biologics, and other plasma-derived or recombinant-biologic companies.

Company	Representative immune globulin products
Grifols	Gamunex-C, Flebogamma DIF
CSL Behring	Privigen, Hizentra
Takeda	Gammagard Liquid, Cuvitru
Octapharma	Octagam, Panzyga, Cutaquig
Kedrion	Gamastan and other plasma-derived products
ADMA Biologics	Asceniv

Competition is determined by more than excipient selection. The decisive factors include plasma collection capacity, fractionation yield, viral inactivation, fill-finish capacity, hospital contracts, specialty-pharmacy access, reimbursement, and supply reliability.

Which companies are challenging Gamunex-C through generic or biosimilar pathways?

A conventional generic challenge is not the principal route. The relevant route is a follow-on biologic or a separately licensed immune globulin product. A 351(k) applicant would need to demonstrate biosimilarity to the reference product, while a product with meaningful differences could require a standalone 351(a) biologics license.

Biosimilar risk is moderate at the product-class level but difficult to quantify for Gamunex-C specifically. Immune globulin manufacturing has high entry barriers:

• access to qualified plasma;
• large-scale fractionation;
• donor screening and viral safety;
• extensive release testing;
• potency assays;
• clinical and immunogenicity requirements;
• limited manufacturing redundancy.

The absence of an active formulation patent does not make entry easy. It shifts the barrier from legal exclusivity to industrial capability and regulatory evidence.

What patent litigation or settlement agreements affect Gamunex-C?

There is no broadly recognized current Paragraph IV litigation pathway for Gamunex-C comparable to the disputes surrounding branded small-molecule drugs. Paragraph IV certifications apply to listed patents associated with an ANDA. Gamunex-C is a biologic and is not ordinarily challenged through that mechanism.

Any relevant dispute would more likely involve:

• patent infringement over purification or formulation technology;
• biosimilar patent-exchange procedures;
• manufacturing-process patents;
• trade-secret claims;
• licensing disputes;
• antitrust or contracting issues involving plasma supply.

Publicly available information does not establish a current Gamunex-C settlement agreement that materially controls market entry. Commercial parties should distinguish a product-specific settlement from broader immune globulin litigation involving another manufacturer or indication.

How strong is the Gamunex-C patent estate?

The patent estate appears weaker as a current exclusionary tool than the product’s manufacturing position. Its practical strength can be summarized as follows:

Asset category	Current strategic strength
Basic glycine formulation	Low, because the concept is old and broadly used
Specific formulation ranges	Potentially moderate if unexpired and technically narrow
Purification and viral-inactivation process	Moderate to high if claims remain unexpired and difficult to design around
Manufacturing know-how	High commercial importance, even without patent protection
Plasma supply network	High barrier, not a conventional patent right
Device and packaging systems	Variable; may create current patent opportunities
Indication patents	Potentially relevant by indication, but subject to claim scope and validity
Product-specific regulatory exclusivity	Limited for an established biologic

A proper freedom-to-operate analysis would require claim-by-claim review of U.S., European, Canadian, Japanese, and other jurisdictional records. The commercial conclusion is more direct: excipient choice alone is unlikely to provide durable exclusivity for a new competitor.

What generic launch scenarios exist for Gamunex-C?

Scenario 1: Direct follow-on immune globulin

A competitor launches a highly similar 10% intravenous immune globulin using glycine or another established stabilizer. Price competition is possible, but hospital and specialty-pharmacy uptake would depend on supply reliability, contracting, and clinical familiarity.

Scenario 2: Differentiated subcutaneous product

A competitor uses higher concentration, improved injection volume, or a more convenient delivery device. This scenario creates stronger commercial differentiation than a simple excipient substitution.

Scenario 3: Supply-constrained market entry

A new manufacturer gains share during shortages or allocation periods. In immune globulin, dependable supply can be more valuable than modest price reductions.

Scenario 4: Contract manufacturing and regional expansion

A qualified manufacturer supports regional products in markets where plasma-derived immunoglobulin access is limited. Excipient standardization and a robust analytical package can shorten technology-transfer timelines.

What geographic coverage applies to Gamunex-C?

Gamunex-C’s commercial position varies by jurisdiction because approval status, patent terms, biologics exclusivity, procurement systems, and substitution rules differ. The United States is governed by the FDA biologics framework. Europe applies centralized or national biologics procedures and does not use the U.S. Orange Book system. Canada, Japan, Australia, and emerging markets apply separate biologics and patent regimes.

The most transferable assets are not the brand name or the glycine concept. They are:

• validated manufacturing processes;
• analytical methods;
• quality systems;
• plasma sourcing;
• cold-chain logistics;
• device compatibility data;
• regulatory dossiers.

What revenue exposure does Gamunex-C create?

Gamunex-C revenue is exposed to the overall immune globulin market rather than a conventional patent cliff. Grifols reports immunoglobulin performance within broader company and business-unit disclosures, and public filings do not consistently provide a standalone Gamunex-C revenue line.[3]

Revenue exposure is shaped by:

• plasma collection volume;
• donor recruitment costs;
• fractionation yield;
• hospital and specialty-pharmacy contracts;
• reimbursement;
• product allocation;
• supply interruptions;
• demand for primary immunodeficiency and neurologic indications.

A loss of formulation exclusivity would not automatically produce immediate generic erosion. Entry depends on whether a competitor can secure plasma, obtain licensure, demonstrate consistent quality, and deliver sufficient volumes.

Key Takeaways

• Gamunex-C uses a glycine-stabilized, preservative-free 10% human immune globulin formulation.
• Glycine supports a simple and established excipient strategy but is unlikely to provide strong current patent exclusivity by itself.
• Gamunex-C is regulated as a biologic under BLA 125122, not as a conventional Orange Book small molecule.
• Paragraph IV litigation is generally not the relevant generic-entry mechanism.
• The principal barriers are plasma supply, fractionation, viral safety, analytical comparability, manufacturing scale, and regulatory execution.
• Commercial opportunities are strongest in subcutaneous delivery, higher-concentration formulations, packaging, devices, supply assurance, and follow-on biologic manufacturing.
• Public company disclosures do not provide a consistently reported standalone Gamunex-C revenue figure.
• For investors and potential entrants, the product’s manufacturing and supply-chain position is more defensible than the basic glycine formulation concept.

FAQs About Gamunex-C Excipients and Market Entry

Does Gamunex-C contain sucrose?

No. Gamunex-C uses glycine as its principal stabilizing excipient and does not use sucrose as the formulation stabilizer identified in the U.S. prescribing information.[1]

Can glycine be replaced in a Gamunex-C follow-on product?

Yes, a follow-on developer can evaluate another established excipient, but the change would require formulation development, stability data, analytical comparability, and regulatory justification. A different excipient may affect aggregation, osmolality, tolerability, and administration.

Is Gamunex-C interchangeable with all 10% immune globulin products?

No. Concentration alone does not establish interchangeability. Product-specific labeling, clinical indication, route, administration rate, FDA designation, and state substitution rules must be considered.

Is Gamunex-C vulnerable to biosimilar competition?

At the product-class level, yes. The practical risk is moderated by the cost and complexity of plasma-derived immune globulin manufacturing, supply qualification, and regulatory comparability.

What is the most attractive commercial opportunity linked to the Gamunex-C formulation?

The strongest opportunity is usually not bulk glycine supply. It is a differentiated delivery or manufacturing platform that improves stability, injection volume, administration convenience, device compatibility, or supply reliability while using established excipients.

References

1. U.S. Food and Drug Administration. (2023). Gamunex-C: Immune globulin injection, human, 10% prescribing information. Grifols Therapeutics LLC.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. Grifols, S.A. (2023). Annual report 2023. Barcelona, Spain: Grifols.